Does PTCY increase the risk of infections?
BK virus
Bloodstream infections
Cyclophosphamide
Cytomegalovirus
Fungal infections
Multidrug resistant bacteria
Journal
Blood reviews
ISSN: 1532-1681
Titre abrégé: Blood Rev
Pays: England
ID NLM: 8708558
Informations de publication
Date de publication:
Nov 2023
Nov 2023
Historique:
received:
21
02
2023
revised:
10
04
2023
accepted:
18
04
2023
medline:
6
12
2023
pubmed:
30
4
2023
entrez:
29
4
2023
Statut:
ppublish
Résumé
PTCY has been mainly used in haploidentical transplant (haploHSCT), but its use in matched donors allowed better evaluation of infectious risk conferred separately by PTCY or donor type. PTCY increased the risk of bacterial infections, both in haploidentical and matched donors, mainly pre-engraftment bacteremias. Bacterial infections, particularly due to multidrug-resistant Gram-negatives, were main causes of infection-related deaths. Higher rates of CMV and other viral infections were reported, mainly in haploHSCT. The role of donor might be more important than the role of PTCY. PTCY increased the risk of BK virus associated hemorrhagic cystitis, and seemed associated with higher risk of respiratory viral infections. Fungal infections were frequent in haploHSCT PCTY cohorts without mold active prophylaxis, but the exact role of PTCY needs to be established. Infections appear to be increased in patients receiving PTCY, although the exact role of GvHD prophylaxis and donor type can only be assessed in prospective trials.
Identifiants
pubmed: 37120352
pii: S0268-960X(23)00053-X
doi: 10.1016/j.blre.2023.101092
pii:
doi:
Substances chimiques
Cyclophosphamide
8N3DW7272P
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
101092Informations de copyright
Copyright © 2023 Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest None.